1177P - FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France

Background

Liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, offers a non-invasive alternative for molecular profiling in oncology, facilitating the advancement of precision medicine. This method provides dynamic insights into tumor evolution and therapy resistance mechanisms without the need for invasive tissue biopsies.

Methods

Since December 2020, Gustave Roussy has incorporated liquid biopsy into its precision oncology workflows (STING: NCT04932525; PRISM PORTAL: NCT05283044), averaging 50 analyses per week using the FL1CDx platform (Penzberg, Germany). All patient samples are evaluated by a Molecular Tumor Board (MTB), which provides personalized therapeutic recommendations based on ctDNA profiles.

Results

Through the monocentric STING trial, over 7037 patients have been evaluated, with an additional 1500 patients assessed through the multicentric PRISM-portal trial across 26 French hospitals. The average time from sample collection to actionable results was 12 days in the STING trial. Actionable genetic alterations were identified in 56% (3869/7037) of patients. The MTB recommended matched therapies for 57% (2227/3908) of these patients, leading to 2485 therapeutic recommendations: clinical trials (72.6%, n=1806), off-label/compassionate use (9.9%, n=246), approved drugs (11.3%, n=281), and early access programs (6.2%, n=155). The PRISM-portal trial demonstrated similar efficacy and turnaround times.

Conclusions

Comprehensive ctDNA profiling using extensive panels has proven effective in matching advanced cancer patients with targeted therapies. Leveraging its expertise, Gustave Roussy has partnered with Roche and Foundation Medicine to perform these analyses in its ISO15189 certified laboratory, contributing to the establishment of the FRESH program (French Hub for Liquid Biopsy). This initiative seeks to broaden access to precise molecular diagnostics and tailored therapies across France. Ongoing enrollment in both the STING and PRISM-portal trials underscores the commitment to validating liquid biopsy’s clinical utility and its role in enhancing routine cancer care.

Clinical trial identification

STING: NCT04932525; PRISM PORTAL: NCT05283044.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Roche.

Disclosure

E. Rouleau: Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Advisory Board: GSK, BMS, Clovis, Roche, Amgen. All other authors have declared no conflicts of interest.